MedTrace Logo

Viviant 20mg Special Investigation (Regulatory Post Marketing Commitment Plan)

NCT01470326 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3187

Last updated 2018-11-05

Study results available
· View outcomes & findings →

Summary

In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.

Conditions

Interventions

DRUG

Bazedoxifene

For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2016-06-30
Completion
2016-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01470326 on ClinicalTrials.gov